1 |
Macpherson I, Abeysekera KWM, Harris R, Mansour D, Mcpherson S, Rowe I, Rosenberg W, Dillon JF, Yeoman A. Identification of liver disease: why and how. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101833] [Reference Citation Analysis]
|
2 |
Subhani M, Jones KA, Sprange K, Rennick-Egglestone S, Knight H, Morling JR, Enki DG, Wragg A, Ryder SD. Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD)? protocol for a feasibility randomised controlled trial. BMJ Open 2021;11:e054954. [PMID: 34732502 DOI: 10.1136/bmjopen-2021-054954] [Reference Citation Analysis]
|
3 |
Smith A, Glyn-Owen K, Buchanan R. Comment on 'Does Advice Based on Biomarkers of Liver Injury or Non-Invasive Tests of Liver Fibrosis Impact High-Risk Drinking Behaviour: A Systematic Review and Meta-Analysis'. Alcohol Alcohol 2021;56:625. [PMID: 33763703 DOI: 10.1093/alcalc/agab023] [Reference Citation Analysis]
|
4 |
Subhani M, Harman DJ, Scott RA, Bennett L, Wilkes EA, James MW, Aithal GP, Ryder SD, Guha IN. Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour? Biomedicines 2022;10:477. [DOI: 10.3390/biomedicines10020477] [Reference Citation Analysis]
|
5 |
Subhani M, Knight H, Ryder S, Morling JR. Reply to Smith et al. Regarding 'Does Advice Based on Biomarkers of Liver Injury or Non-Invasive Tests of Liver Fibrosis Impact High-Risk Drinking Behaviour: A Systematic Review with Meta-Analysis'. Alcohol Alcohol 2021:agab025. [PMID: 33822871 DOI: 10.1093/alcalc/agab025] [Reference Citation Analysis]
|